Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target

Benzinga · 2d ago
Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $41 price target.